Grace Therapeutics submitted an NDA for GTx-104 review to the FDA.
6 reports, 2 independent
Updated Aug 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 6
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Grace Therapeutics submitted an NDA for GTx-104 review to the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Grace Therapeutics submitted NDA for GTx-104 review.1 source
Grace Therapeutics submitted a new drug application for GTx-104 and filed financial results with the SEC.1 source
Keep exploring
The entities involved
Related events
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Avexitide received FDA Breakthrough Therapy designation.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- The FDA is ending compounding grace periods as competition intensifies and Lilly faces pipeline setbacks in the GLP-1 market.
Coverage
Newest first; wire copies grouped- GlobeNewswireGrace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission S
- Zacks Small Cap ResearchGRCE: Looking Ahead to Acceptance By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) reported first quarter fiscal year 2026 results highli
- GlobeNewswireGrace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking App
- Unknown outlet
- Unknown outlet
- Unknown outlet